Sales Related Topics 
Bio Pharma Dive
NOVEMBER 3, 2022
The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product
Pharmaceutical Technology
FEBRUARY 21, 2023
Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JANUARY 24, 2023
The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal
Bio Pharma Dive
JANUARY 6, 2023
The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Pharma Phorum
OCTOBER 13, 2021
Create and disseminate sales support materials. Manage and develop sales team (sales manager role only). Proven experience of working as part of a sales team. Proven work experience working in a sales-based role. The post Sales manager appeared first on.
Bio Pharma Dive
JULY 27, 2022
A manufacturing issue for Breyanzi, meanwhile, impacted sales Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.
Bio Pharma Dive
FEBRUARY 3, 2023
The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review
Bio Pharma Dive
FEBRUARY 27, 2023
Citing people familiar with the talks, The Wall Street Journal reported over the weekend that Pfizer is trying to acquire Seagen and its suite of cancer therapies in a deal that could be worth more than $30 billion
Bio Pharma Dive
MARCH 13, 2023
In its first full quarter on the market, Amylyx’s Relyvrio generated revenue just shy of $22 million, or roughly five times what some analysts were forecasting a month ago
Bio Pharma Dive
NOVEMBER 9, 2022
While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability
Bio Pharma Dive
FEBRUARY 2, 2023
Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies
Bio Pharma Dive
JANUARY 31, 2023
The company expects yearly revenue from Comirnaty and Paxlovid to fall by nearly two thirds in 2023 amid lower vaccination rates and a shift to private market sales
Pharmaceutical Technology
FEBRUARY 3, 2023
Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter.
Bio Pharma Dive
AUGUST 23, 2022
The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales
Bio Pharma Dive
JULY 21, 2021
billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks The pharmaceutical company expects $2.5
Bio Pharma Dive
JANUARY 25, 2023
Carvykti, which was approved a year ago for hard-to-treat multiple myeloma, generated $55 million in fourth quarter sales, the same as it earned between July and September
Bio Pharma Dive
NOVEMBER 2, 2022
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro
Bio Pharma Dive
AUGUST 17, 2022
The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics
Pharma Mirror
OCTOBER 17, 2022
The post Artificial Intelligence (AI) in Pharma Sales and Marketing appeared first on Pharma Mirror Magazine. Pharmaceutical Articles artificial intelligence Pharma Sales and MarketingWhat is AI?
Bio Pharma Dive
FEBRUARY 5, 2021
Sales of the antiviral drug accounted for a quarter of the biotech's product revenue in the fourth quarter, disguising hits to its business elsewhere
Bio Pharma Dive
OCTOBER 25, 2022
Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche
Bio Pharma Dive
MARCH 9, 2023
The Novartis division will invest at least $400 million in a new manufacturing facility in Slovenia amid expectations that demand for copycat biologics will surge in the coming years
Pharma Phorum
NOVEMBER 16, 2022
Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports.
Bio Pharma Dive
DECEMBER 22, 2021
Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness
BioSpace
MARCH 13, 2023
Novartis Explores Sale of Certain Ophthalmology Assets 3/14/2023
Pharma Phorum
JUNE 6, 2022
Eversana’s suite of commercialisation tools for pharma companies will soon have a new component – cognitive behavioural training tools designed to improve the performance of sales representatives. Digital News Sales and Marketing digital Sales reps Training
Pharma Phorum
DECEMBER 28, 2022
Selling amid a global pandemic has changed the face of sales forever. This is nowhere more pronounced than for medical device sales teams, who typically schedule regular visits to hospitals and doctors’ offices to create a personal, ongoing connection that drives forward the sales process.
Bio Pharma Dive
JULY 29, 2022
Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence
Bio Pharma Dive
FEBRUARY 17, 2022
The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program
Bio Pharma Dive
APRIL 29, 2021
Both companies blamed the impact of COVID-19 on sharp declines in sales of their shingles, pneumonia and HPV shots
Pharma Phorum
NOVEMBER 9, 2021
COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment of how the sales function should work. The industry faces the dawn of a new age in sales coaching.
Bio Pharma Dive
MAY 4, 2022
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S.
Bio Pharma Dive
OCTOBER 28, 2021
But sales could climb even higher if it works as a preventive treatment too Executives based their projections on contracts already in place for the drug, known as molnupiravir.
Pharma Phorum
DECEMBER 23, 2022
Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. The post 7 commercial, sales, and marketing predictions for 2023 appeared first on.
Bio Pharma Dive
OCTOBER 18, 2021
The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines
Bio Pharma Dive
FEBRUARY 8, 2022
The company estimated revenue from its COVID-19 vaccine and antiviral pill Paxlovid will total $54 billion this year. Curiously, its stock fell by more than 5
Bio Pharma Dive
FEBRUARY 2, 2021
The estimate for 2021 sales, which Pfizer splits with partner BioNTech, would make the vaccine one of the highest-selling medicines in the industry
Bio Pharma Dive
OCTOBER 28, 2022
After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and Johnson & Johnson
Bio Pharma Dive
FEBRUARY 3, 2022
Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage
Pharma Phorum
MARCH 18, 2021
The demise of the pharmaceutical sales representative has been greatly exaggerated over the years. The current restrictions on face-to-face meetings have exacerbated the trend of sales reps’ reduced access to healthcare customers.
Bio Pharma Dive
APRIL 28, 2022
Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs
Bio Pharma Dive
JULY 31, 2020
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations
Expert insights. Personalized for you.
290 
Let's personalize your content